{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:11:58Z","timestamp":1793502718762,"version":"4.5.0"},"reference-count":234,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"DOI":"10.3389\/fpubh.2019.00151","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T11:45:39Z","timestamp":1560253539000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":244,"title":["The \u201cOld\u201d and the \u201cNew\u201d Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How"],"prefix":"10.3389","volume":"7","author":[{"given":"Ilias","family":"Karaiskos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Lagou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Pontikis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Rapti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garyphallia","family":"Poulakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2165\/11315690-000000000-00000","article-title":"Multidrug-resistant Gram-negative infections: what are the treatment options?","volume":"69","author":"Giamarellou","year":"2009","journal-title":"Drugs."},{"key":"B2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pan drug-resistant bacteria: an inter-national expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect."},{"key":"B3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases","volume":"13","author":"Munoz-Price","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"B4","unstructured":"Geneva, SwitzerlandWHO PressAntimicrobial Resistance: No Action Today, No Cure Tomorrow2011"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"B6","unstructured":"Neill, review on antimicrobial resistance, tackling drug-resistant infections globally\n            JamesO\n          2015"},{"key":"B7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.21037\/atm.2018.10.29","article-title":"New treatments of multidrug-resistant Gram-negative ventilator-associated pneumonia","volume":"6","author":"Poulakou","year":"2018","journal-title":"Ann Transl Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cmi.2017.08.030","article-title":"Critically Ill patients study group of the european society of clinical microbiology and infectious disease (ESCMID); Hellenic Society of Chemotherapy (HSC) and Societ\u00e0 Italiana di Terapia Antinfettiva (SITA). Management of KPC-producing Klebsiella pneumoniae infections","volume":"24","author":"Bassetti","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s00134-017-4878-x","article-title":"Antimicrobial resistance in the next 30 years, humankind, bugs and drugs:a visionary approach","volume":"43","author":"Bassetti","year":"2017","journal-title":"Intensive Care Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1473-3099(16)30257-2","article-title":"European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE) working group. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study","volume":"17","author":"Grundmann","year":"2017","journal-title":"Lancet Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1469-0691.2009.03116.x","article-title":"Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues","volume":"16","author":"Miriagou","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"B12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lacta-mases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13613-015-0061-0","article-title":"Mechanisms of antimicrobial resistance in Gram-negative bacilli","volume":"5","author":"Rupp\u00e9","year":"2015","journal-title":"Ann Intensive Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","article-title":"Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study","volume":"16","author":"Liu","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/17425255.2017.1230200","article-title":"Colistin: still a lifesaver for the 21st century?","volume":"13","author":"Karaiskos","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1093\/jac\/dky266","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15","volume":"73","author":"Kazmierczak","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1093\/jac\/dky267","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012\u201315","volume":"73","author":"Kazmierczak","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1128\/AAC.01361-08","article-title":"Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria","volume":"53","author":"Plachouras","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.1128\/AAC.00554-15","article-title":"Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically Ill patients","volume":"59","author":"Karaiskos","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/cid\/ciw839","article-title":"Dosing guidance for intravenous colistin in critically-ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/cid\/civ717","article-title":"Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care?","volume":"61","author":"Dalfino","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/cid\/civ964","article-title":"Updated US and european dose recommendations for intravenous colistin: how do they perform?","volume":"62","author":"Nation","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/14787210.2017.1410434","article-title":"Combination therapy for extensively-drug resistant gram-negative bacteria","volume":"15","author":"Karaiskos","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae:differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3109\/00365548.2011.616221","article-title":"Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria","volume":"44","author":"Dinh","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijantimicag.2013.09.010","article-title":"Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria","volume":"43","author":"Pontikis","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"B32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ijantimicag.2015.07.019","article-title":"The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in In vitro pharmacokinetic\/pharmacodynamic model experiments","volume":"46","author":"Albur","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"B33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/jac\/dkq070","article-title":"Extracellular concentrations of fosfomycin in lung tissue of septic patients","volume":"65","author":"Matzi","year":"2010","journal-title":"J Antimicrob Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/jac\/dkh158","article-title":"Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis","volume":"53","author":"Pfausler","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1128\/AAC.49.11.4448-4454.2005","article-title":"Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles","volume":"49","author":"Sauermann","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijantimicag.2010.09.002","article-title":"Adverse events associated with intravenous fosfomycin","volume":"37","author":"Florent","year":"2011","journal-title":"Int J Antimicrob Agents."},{"key":"B37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cmi.2016.12.005","article-title":"Intravenous fosfomycin \u2013 Back to the future. Systematic review and meta-analysis of the clinical literature","volume":"23","author":"Grabein","year":"2017","journal-title":"Clin Microbiol Infect."},{"key":"B38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","article-title":"Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature","volume":"47","author":"Vardakas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1128\/AAC.00589-13","article-title":"In vitro activity of fosfomycin against a collection of clinical Pseudomonas aeruginosa isolates from 16 spanish hospitals: establishing the validity of standard broth microdilution as susceptibility testing method","volume":"57","author":"D\u00edez-Aguilar","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"pii=1700775","DOI":"10.2807\/1560-7917.ES.2018.23.30.1700775","article-title":"Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014\u20132016","volume":"23","author":"Galani","year":"2018","journal-title":"Eurosurveillance."},{"key":"B41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.diagmicrobio.2018.08.010","article-title":"Activity of fosfomycin when tested against US contemporary bacterial isolates","volume":"93","author":"Flamm","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1093\/jac\/dks270","article-title":"Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases","volume":"67","author":"Karageorgopoulos","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"B43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1469-0691.2009.02921.x","article-title":"Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation","volume":"16","author":"Michalopoulos","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"B44","article-title":"Phenotypic antibiotic resistance in ZEUS: a multi-center, randomized, double-blind phase 2\/3 Study of ZTI-01 versus Piperacillin-Tazobactam (P-T) in the treatment of patients with Complicated Urinary Tract Infections (cUTI) including Acute Pyelonephritis","volume-title":"ID Week","author":"Ellis-Grosse","year":"2017"},{"key":"B45","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017"},{"key":"B46","unstructured":"List of the Names, Pharmaceutical Forms, Strengths of the Medicinal Products, Routes of Administration, Marketing Authorisation Holders in the Member States for Fosfomycin-Containing Medicinal Products2018"},{"key":"B47","unstructured":"NabrivaTherapeutics\n          Nabriva Therapeutics Strengthens Antibiotics Leadership Position With Acquisition of Zavante Therapeutics2018"},{"key":"B48","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ijantimicag.2018.06.014","article-title":"Fosfomycin Etest for Enterobacteriaceae: Interobserver and interlaboratory agreement","volume":"52","author":"van Mens","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"B49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.diagmicrobio.2018.07.014","article-title":"Discrepancies in fosfomycin susceptibility testing of KPC-producing Klebsiella pneumoniae with various commercial methods","volume":"93","author":"Camarlinghi","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B50","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing ; Twenty-Second Informational Supplement. 298","year":"2012"},{"key":"B51","unstructured":"EUCAST Clinical MIC Breakpoints"},{"key":"B52","unstructured":"119Fomicyt 40mg\/ml powder for solution for infusion. Public assessment report. Mutual recognition Procedure. Medicines and Healthcare products. Regulatory Agents2017"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00134-008-1247-9","article-title":"Screening for resistant gram-negative microorganisms to guide empiric therapy of subsequent infection","volume":"34","author":"Papadomichelakis","year":"2008","journal-title":"Intensive Care Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ijantimicag.2013.05.018","article-title":"What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients?","volume":"42","author":"Parker","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"B56","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1128\/AAC.01321-15","article-title":"Population pharmacokinetics of fosfomycin in critically Ill patients","volume":"59","author":"Parker","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1586\/eri.12.138","article-title":"Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective","volume":"10","author":"Daikos","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/cid\/ciw504","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the american thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/jac\/dkx070","article-title":"Pharmacodynamics of colistin and fosfomycin: a \u201ctreasure trove\u201d combination combats KPC-producing Klebsiella pneumoniae","volume":"72","author":"Zhao","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ijantimicag.2017.03.011","article-title":"In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae","volume":"50","author":"Yu","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1128\/AAC.01086-10","article-title":"In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development","volume":"55","author":"Souli","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"B62","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10096-011-1360-5","article-title":"Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates","volume":"31","author":"Samonis","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/jac\/dkr296","article-title":"In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae","volume":"66","author":"Ber\u00e7ot","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"B64","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2147\/IDR.S160474","article-title":"In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae","volume":"11","author":"Yu","year":"2018","journal-title":"Infect Drug Resist"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: nephrotoxicity","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.chest.2016.11.026","article-title":"A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS trial","volume":"151","author":"Kollef","year":"2017","journal-title":"Chest."},{"key":"B67","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/jac\/dky406","article-title":"Fosfomycin in severe infections due to genetically distinct pan-drug-resistant Gram-negative microorganisms: synergy with meropenem","volume":"74","author":"Perdig\u00e3oNeto","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.1128\/AAC.03099-15","article-title":"Pharmacodynamic evaluation of the potential clinical utility of fosfomycin and meropenem in combination therapy against KPC-2-producing Klebsiella pneumoniae","volume":"60","author":"Albiero","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s00134-015-4079-4","article-title":"European society of intensive care medicine. Task force on management and prevention of Acinetobacter baumannii infections in the ICU","volume":"41","author":"Garnacho-Montero","year":"2015","journal-title":"Intensive Care Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1517\/17425255.2011.623126","article-title":"Pharmacokinetic and pharmacodynamic evaluation of tigecycline","volume":"7","author":"Giamarellou","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijantimicag.2009.01.015","article-title":"Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint","volume":"34","author":"Burkhardt","year":"2009","journal-title":"Int J Antimicrob Agents."},{"key":"B72","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/jac\/dkp056","article-title":"Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model","volume":"63","author":"Koomanachai","year":"2009","journal-title":"J Antimicrob Chemother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijantimicag.2014.07.014","article-title":"High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections","volume":"45","author":"Routsi","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2014.01.006","article-title":"Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections","volume":"44","author":"Falagas","year":"2014","journal-title":"Int J Antimicrob Agents."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00134-014-3343-3","article-title":"Is there a future for tigecycline?","volume":"40","author":"Bassetti","year":"2014","journal-title":"Intensive Care Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K.pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijantimicag.2010.10.031","article-title":"Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay","volume":"37","author":"Pournaras","year":"2011","journal-title":"Int J Antimicrob Agents."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e0126479","DOI":"10.1371\/journal.pone.0126479","article-title":"Three dimensional checkerboard synergy analysis of colistin, meropenem, tigecycline against multidrug-resistant clinical Klebsiella pneumonia isolates","volume":"10","author":"Stein","year":"2015","journal-title":"PLoS ONE"},{"key":"B79","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1128\/AAC.02449-14","article-title":"In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae","volume":"58","author":"Betts","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B80","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1128\/AAC.01624-13","article-title":"In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii","volume":"58","author":"Hagihara","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B81","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1128\/AAC.00323-15","article-title":"Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay","volume":"59","author":"Toledo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B82","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2253-13-13","article-title":"KPC-3 Klebsiella pneumoniae ST258 clone infection in postoperativeabdominal surgery patients in an intensive care setting: analysis of a case seriesof 30 patients","volume":"13","author":"Di Carlo","year":"2013","journal-title":"BMC Anesthesiol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e9961","DOI":"10.1097\/MD.0000000000009961","article-title":"High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study","volume":"97","author":"Geng","year":"2018","journal-title":"Medicine."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e3126","DOI":"10.1097\/MD.0000000000003126","article-title":"Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis","volume":"95","author":"Ni","year":"2016","journal-title":"Medicine."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1128\/AAC.01232-12","article-title":"Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia","volume":"57","author":"Ramirez","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e01074","DOI":"10.1128\/AAC.01074-18","article-title":"In vivo efficacy of plazomicin alone or in combination with meropenem or tigecycline against Enterobacteriaceae isolates exhibiting various resistance mechanisms in an immunocompetent murine septicemia model","volume":"62","author":"Abdelraouf","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B88","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/14787210.2017.1316193","article-title":"Aminoglycosides against carbapenem resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility","volume":"15","author":"Zavascki","year":"2017","journal-title":"Expert Rev Anti Infect Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.idc.2016.02.011","article-title":"Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases","volume":"30","author":"Doi","year":"2016","journal-title":"Infect Dis Clin North Am."},{"key":"B90","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1128\/AAC.00099-14","article-title":"Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycosidemodifying enzymes, which exert differing effects on plazomicin and other agents","volume":"58","author":"Almaghrabi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B91","doi-asserted-by":"publisher","first-page":"7597","DOI":"10.1128\/AAC.03831-14","article-title":"KPC-producing Klebsiella pneumoniae strains that harbor AAC(6\u2032)-Ib exhibit intermediate resistance to amikacin","volume":"58","author":"Bremmer","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B92","doi-asserted-by":"publisher","first-page":"20939","DOI":"10.2807\/1560-7917.ES2014.19.42.20939","article-title":"Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013\u2013April 2014","volume":"19","author":"Monaco","year":"2014","journal-title":"Euro Surveill"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.clinthera.2012.05.002","article-title":"Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort","volume":"34","author":"Alexander","year":"2012","journal-title":"Clin Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1128\/AAC.00387-11","article-title":"Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem resistant Klebsiella pneumoniae from urine","volume":"55","author":"Satlin","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B95","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1128\/CMR.05035-11","article-title":"Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions","volume":"25","author":"Tzouvelekis","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"B96","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cmi.2017.04.011","article-title":"Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases","volume":"23","author":"Rello","year":"2017","journal-title":"Clin Microbiol Infect."},{"key":"B97","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/14787210.2017.1268052","article-title":"Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges","volume":"15","author":"Poulakou","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B98","volume-title":"Performance standards for antimicrobial susceptibility testing. 28th Informational Supplement M100.","year":"2018"},{"key":"B99","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jac\/dkv291","article-title":"Impact of 30 mg\/kg amikacin and 8 mg\/kg gentamicin on serum concentrations in critically ill patients with severe sepsis","volume":"71","author":"Roger","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"B100","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijantimicag.2015.02.009","article-title":"Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations","volume":"46","author":"Roger","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"B101","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1007\/s00134-014-3276-x","article-title":"Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg\/kg total body weight regimen","volume":"40","author":"De Montmollin","year":"2014","journal-title":"Intensive Care Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijantimicag.2011.03.022","article-title":"Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity","volume":"38","author":"Galvez","year":"2011","journal-title":"Int J Antimicrob Agents."},{"key":"B103","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/cc8945","article-title":"Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit Care"},{"key":"B104","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00228-014-1766-y","article-title":"Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia","volume":"71","author":"Burdet","year":"2015","journal-title":"Eur J Clin Pharmacol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/jac\/dkv491","article-title":"A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study","volume":"71","author":"Brasseur","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"B106","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/jac\/dku432","article-title":"Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae","volume":"70","author":"Gonzalez-Padilla","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"B107","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1128\/AAC.02638-15","article-title":"Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae","volume":"60","author":"Shields","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/jac\/dku495","article-title":"Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae","volume":"70","author":"Van Duin","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"B109","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/jac\/dkm193","article-title":"Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Vidal","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"B110","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000440867","article-title":"Acute kidney injury and renal recovery with the use of aminoglycosides: a large retrospective study","volume":"131","author":"Paquette","year":"2015","journal-title":"Nephron"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2146\/ajhp140564","article-title":"Once-daily aminoglycoside dosing: an update on current literature","volume":"72","author":"Stankowicz","year":"2015","journal-title":"Am J Health Syst Pharm."},{"key":"B112","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1093\/jac\/dkw296","article-title":"Aminoglycoside-associated acute kidney injury in elderly patients with and without shock","volume":"71","author":"Ong","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"B113","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1128\/AAC.00296-10","article-title":"Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa","volume":"54","author":"Moy\u00e1","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B114","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"B115","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/17425255.2019.1563071","article-title":"Novel \u03b2-lactam-\u03b2-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens","volume":"15","author":"Karaiskos","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B116","unstructured":"Summary of Product Characteristics: European Medicines Agency SPC for ceftazidime avibactam (Zavicefta\u2122)2016"},{"key":"B117","unstructured":"FDA2017"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1517\/13543784.2015.1095180","article-title":"Plazomicin: an investigational therapy for the treatment of urinary tract infections","volume":"24","author":"Karaiskos","year":"2015","journal-title":"Expert Opin Investig Drugs."},{"key":"B119","unstructured":"FDA Approval of Plazomicin (ZEMDRI\u2122)2018"},{"key":"B120","unstructured":"Tetraphase, Announces FDA Approval of Eravacyline for the Treatment of cIAIs,"},{"key":"B121","unstructured":"Tetraphase Announces EMA Approval of Eravacyline for the Treatment of cIAIs2018"},{"key":"B122","unstructured":"2018"},{"key":"B123","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13613-016-0211-z","article-title":"Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock","volume":"6","author":"Allou","year":"2016","journal-title":"Ann Intensive Care."},{"key":"B124","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/infdis\/jis766","article-title":"Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. Pneumoniae","volume":"207","author":"Hirsch","year":"2013","journal-title":"J Infect Dis"},{"key":"B125","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4021\/jocmr551w","article-title":"In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae","volume":"3","author":"Le","year":"2011","journal-title":"J Clin Med Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijantimicag.2017.08.019","article-title":"Italian Study Group on Resistant Infections of the Societa\u2018 Italiana Terapia Antinfettiva (ISGRI-SITA). Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection","volume":"51","author":"Giannella","year":"2018","journal-title":"Int J Antimicrob Agents."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1128\/AAC.00782-08","article-title":"Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections","volume":"53","author":"Daikos","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"B128","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1128\/AAC.01420-10","article-title":"Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae","volume":"55","author":"Bulik","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B129","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/jac\/dkv294","article-title":"In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae","volume":"71","author":"Poirel","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"B130","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1128\/AAC.02399-12","article-title":"Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemaseproducing pandrug-resistant Klebsiella pneumoniae","volume":"57","author":"Giamarellou","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"B131","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jinf.2016.10.002","article-title":"Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp)","volume":"74","author":"Oliva","year":"2017","journal-title":"J Infect."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s10096-017-2936-5","article-title":"Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae","volume":"36","author":"Souli","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"B133","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13054-017-1769-z","article-title":"Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case control study","volume":"21","author":"De Pascale","year":"2017","journal-title":"Crit Care"},{"key":"B134","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1099\/jmm.0.000725","article-title":"In vitro evaluation of double-carbapenem combinations against OXA-48-producing Klebsiella pneumoniae isolates using time-kill studies","volume":"67","author":"Galani","year":"2018","journal-title":"J Med Microbiol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"e12795","DOI":"10.1111\/tid.12795","article-title":"Double carbapenem and oral fosfomycin for the treatment of complicated urinary tract infections caused by blaNDM -harboring Enterobacteriaceae in kidney transplantation","volume":"20","author":"Rosa","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"B136","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","article-title":"Ceftolozane\/tazobactam:place in therapy","volume":"16","author":"Giacobbe","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B137","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u201cproblem\u201d Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"B138","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B139","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres 2012","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1093\/jac\/dky225","article-title":"Antibacterial effect of ceftolozane\/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an In vitro pharmacokinetic model of infection","volume":"73","author":"Noel","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/jac\/dkz030","article-title":"High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial","volume":"74","author":"P\u00e9rez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/Tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet."},{"key":"B144","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1093\/jac\/dks246","article-title":"Intrapulmonary penetration of ceftolozane\/tazobactam and piperacillin\/tazobactam in healthy adult subjects","volume":"67","author":"Chandorkar","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"B145","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/jcph.566","article-title":"Ceftolozane\/tazobactam pharmacokinetic\/ pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia","volume":"56","author":"Xiao","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40121-016-0143-9","article-title":"PK\/PD target attainment with ceftolozane\/tazobactam using monte carlo simulation in patients with various degrees of renal function, including augmented renal clearance and end-stage renal disease","volume":"6","author":"Xiao","year":"2017","journal-title":"Infect Dis Ther"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2174\/97816810814031150101","article-title":"Ceftolozane-tazobactam pharmacokinetics in a critically Ill patient on continuous venovenous hemofiltration","volume":"60","author":"Oliver","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"B148","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/phar.1744","article-title":"Ceftolozane\/tazobactam pharmacokinetics in a critically Ill adult receiving continuous renal replacement therapy","volume":"36","author":"Bremmer","year":"2016","journal-title":"Pharmacotherapy"},{"key":"B149","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ijantimicag.2016.06.005","article-title":"Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane\/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration","volume":"48","author":"Kuti","year":"2016","journal-title":"Int J Antimicrob Agents."},{"key":"B150","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1093\/jac\/dkx221","article-title":"Determination of alternative ceftolozane\/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg\/L","volume":"72","author":"Natesan","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"B151","doi-asserted-by":"publisher","first-page":"pii e02136","DOI":"10.1128\/AAC.02136-16","article-title":"Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections","volume":"61","author":"Cast\u00f3n","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B152","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis."},{"key":"B153","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B154","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s15010-018-1133-5","article-title":"Ceftolozane\/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections","volume":"46","author":"Escol\u00e0-Verg\u00e9","year":"2018","journal-title":"Infection."},{"key":"B155","doi-asserted-by":"publisher","first-page":"e0195757","DOI":"10.1371\/journal.pone.0195757","article-title":"Carbapenem-resistant Gram-negative pathogens in a German university medical center: prevalence, clinical implications and the role of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"13","author":"Katchanov","year":"2018","journal-title":"PLoS ONE"},{"key":"B156","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jgar.2018.01.010","article-title":"Clinical experience with ceftolozane\/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa","volume":"13","author":"Xipell","year":"2018","journal-title":"J Glob Antimicrob Resist."},{"key":"B157","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/jac\/dkw486","volume":"72","author":"Kullar","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"B158","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/14787210.2018.1473079","article-title":"Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia","volume":"16","author":"Plant","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B159","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"B160","doi-asserted-by":"publisher","first-page":"e01350","DOI":"10.1128\/AAC.01350-17","article-title":"In vitro comparison of ceftolozane-tazobactam to traditional beta-lactams and ceftolozane-tazobactam as an alternative to combination antimicrobial therapy for Pseudomonas aeruginosa","volume":"61","author":"Goodlet","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B161","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/QCO.0000000000000505","article-title":"Rational approach in the management of Pseudomonas aeruginosa infections","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"B162","doi-asserted-by":"publisher","first-page":"e00028","DOI":"10.1183\/23120541.00028-2018","article-title":"Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia","volume":"4","author":"Torres","year":"2018","journal-title":"ERJ Open Res"},{"key":"B163","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1128\/AAC.02894-14","article-title":"Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against beta-lactamase producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"58","author":"Keepers","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B164","unstructured":"Allergan Summary of Product Characteristics Food and Drug Administration Ceftazidime avibactam (Avycaz\u2122)"},{"key":"B165","doi-asserted-by":"publisher","first-page":"e02083","DOI":"10.1128\/AAC.02083-16","article-title":"Antimicrobial activity of ceftazidime-avibactam when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in U.S. Medical Centers, 2011 to 2015","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B166","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1128\/AAC.49.11.4760-4762.2005","article-title":"Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase","volume":"49","author":"Alba","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1128\/AAC.04218-14","article-title":"In vitro antibacterial activity of the ceftazidime-avibactam combination against Enterobacteriaceae, including strains with well-characterized \u03b2-lactamases","volume":"59","author":"Levasseur","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"B168","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1128\/AAC.00548-15","article-title":"Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum \u03b2-lactamases, and porin mutations on the In vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae","volume":"59","author":"Shields","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B169","doi-asserted-by":"publisher","first-page":"6490","DOI":"10.1128\/AAC.03579-14","article-title":"Efficacy of a ceftazidime-avibactam combination in a murine model of septicemia caused by Enterobacteriaceae species producing AmpC or extended-spectrum beta-lactamases","volume":"58","author":"Levasseur","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B170","doi-asserted-by":"publisher","first-page":"e01964","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B171","doi-asserted-by":"publisher","first-page":"e00528","DOI":"10.1128\/mBio.00528-17","article-title":"Klebsiella pneumoniae Carbapenemase-2 (KPC-2), substitutions at ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from \u03b2-lactamase protein engineering","volume":"8","author":"Barnes","year":"2017","journal-title":"MBio."},{"key":"B172","doi-asserted-by":"publisher","first-page":"e00451","DOI":"10.1128\/AAC.00451-17","article-title":"Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the KPC-2 \u03b2-lactamase","volume":"61","author":"Compain","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B173","doi-asserted-by":"publisher","first-page":"e02534","DOI":"10.1128\/AAC.02534-16","article-title":"Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum \u03b2-lactamases","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B174","doi-asserted-by":"publisher","first-page":"e00079","DOI":"10.1128\/AAC.00079-17","article-title":"In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1128\/AAC.06064-11","article-title":"In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates","volume":"56","author":"Levasseur","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"B176","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.diagmicrobio.2014.07.005","article-title":"Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program 2011","volume":"80","author":"Flamm","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B177","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1128\/AAC.05024-14","article-title":"Ceftazidime- avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B178","doi-asserted-by":"publisher","first-page":"7358","DOI":"10.1128\/AAC.03930-14","article-title":"Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel \u03b2-lactamases, GES-22 and VIM-35","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B179","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jiac.2015.04.006","article-title":"Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers","volume":"21","author":"Tominaga","year":"2015","journal-title":"J Infect Chemother."},{"key":"B180","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jcph.793","article-title":"Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment","volume":"57","author":"Merdjan","year":"2017","journal-title":"J Clin Pharmacol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1093\/jac\/dkv170","article-title":"Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens","volume":"70","author":"Nicolau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection:results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B183","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents."},{"key":"B184","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B185","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B186","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B187","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B188","doi-asserted-by":"publisher","first-page":"e00449","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B189","doi-asserted-by":"publisher","first-page":"e02497","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B190","doi-asserted-by":"publisher","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B191","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactamversus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int J Infect Dis."},{"key":"B192","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B193","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis."},{"key":"B194","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/ avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae","volume":"73","author":"Sousa","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"B195","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijantimicag.2018.07.004","article-title":"Evaluation of efficacy and safety of ceftazidime-avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis","volume":"52","author":"Zhong","year":"2018","journal-title":"Int J Antimicrob Agents."},{"key":"B196","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs. class A serine carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem."},{"key":"B197","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1128\/AAC.00843-15","article-title":"Activity of meropenem combined with RPX7009, a novel beta-lactamase inhibitor, against Gram-negative clinical isolates in New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B198","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1128\/AAC.00711-16","article-title":"Effect of the beta-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"B199","doi-asserted-by":"publisher","first-page":"e00567","DOI":"10.1128\/AAC.00567-17","article-title":"Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, kpc producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B200","doi-asserted-by":"publisher","first-page":"e01443","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B201","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ccm.2018.08.007","article-title":"New antibiotics for pneumonia","volume":"39","author":"Bassetti","year":"2018","journal-title":"Clin Chest Med"},{"key":"B202","doi-asserted-by":"publisher","first-page":"6326","DOI":"10.1128\/AAC.00568-16","article-title":"Phase 1 study of the safety, tolerability, and pharmacokinetics of the b-lactamase inhibitor vaborbactam (RPX7009) in healthy adult subjects","volume":"60","author":"Griffith","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"B203","doi-asserted-by":"publisher","first-page":"e01904","DOI":"10.1128\/AAC.01904-17","article-title":"In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae","volume":"62","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B204","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs. piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"B205","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"B206","unstructured":"Website of European Medicines Agency2019"},{"key":"B207","unstructured":"2019"},{"key":"B208","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1586\/eri.12.25","article-title":"Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin, and amikacin","volume":"10","author":"Zhanel","year":"2012","journal-title":"Expert Rev Anti Infect Ther."},{"key":"B209","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem resistant Enterobacteriaceae isolates","volume":"66","author":"Livermore","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"B210","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1128\/AAC.00556-09","article-title":"ACHN-490, a neoglycoside with potent In vitro activity against multidrug-resistant Klebsiella pneumoniae isolates","volume":"53","author":"Endimiani","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"B211","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1128\/AAC.02744-13","article-title":"In vitro activity of plazomicin against 5,015 Gram-negative and Gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011\u20132012","volume":"58","author":"Walkty","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B212","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/jac\/dkq459","article-title":"Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City","volume":"66","author":"Landman","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"B213","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1179\/1973947812Y.0000000015","article-title":"Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli and Enterobacter spp. from Athens, Greece","volume":"24","author":"Galani","year":"2012","journal-title":"J Chemother."},{"key":"B214","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1093\/jac\/dkx239","volume":"72","author":"Denervaud-Tendon","year":"2017","journal-title":"Antimicrob Chemother"},{"key":"B215","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.1128\/AAC.00624-11","article-title":"Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects","volume":"55","author":"Cass","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B216","unstructured":"Results of the EPIC Trial Released in Achaogen's2016"},{"key":"B217","doi-asserted-by":"publisher","first-page":"S531","DOI":"10.1093\/ofid\/ofx163.1383","article-title":"Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE): results from the CARE Study","volume":"4","author":"McKinnell","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"B218","article-title":"Plazomicin is associated with improved survival and safety compared to colistin in serious carbapenem-resistant Enterobacteriaceae (CRE) infections: results of the CARE study","volume-title":"Presented at the Annual Meeting of the American Society of Microbiology","author":"Connolly","year":"2017"},{"key":"B219","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N Engl J Med"},{"key":"B220","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1517\/13543784.2014.965253","article-title":"Eravacycline for the treatment of intra-abdominal Infections","volume":"23","author":"Bassetti","year":"2014","journal-title":"Expert Opin Investig Drugs."},{"key":"B221","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/AAC.04809-14","article-title":"Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates from New York City","volume":"59","author":"Abdallah","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"B222","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B223","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1128\/AAC.04354-14","article-title":"Eravacycline (TP-434) is efficacious in animal models of infection","volume":"59","author":"Grossman","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"B224","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1128\/AAC.02036-13","article-title":"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B225","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","article-title":"In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii","volume":"51","author":"Seifert","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"B226","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections","author":"Solomkin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B228","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1128\/AAC.00264-16","article-title":"Successful treatment of bloodstream infection due to metallo-\u03b2-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient","volume":"60","author":"Mojica","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/jac\/dkx496","article-title":"Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection","volume":"73","author":"Shaw","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"B230","doi-asserted-by":"publisher","first-page":"e01969","DOI":"10.1128\/AAC.01969-17","article-title":"Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an In vitro hollow-fiber model","volume":"62","author":"Sabet","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B231","doi-asserted-by":"publisher","first-page":"e01694","DOI":"10.1128\/AAC.01694-17","article-title":"Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae","volume":"61","author":"Sun","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy988","article-title":"Treatment outcomes of colistin and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial","author":"Dickstein","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B233","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis","volume":"72","author":"Zusman","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"B234","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.idc.2009.01.004","volume":"23","author":"Paul","year":"2009","journal-title":"Infect Dis Clin North Am"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpubh.2019.00151\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T11:45:45Z","timestamp":1560253545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpubh.2019.00151\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":234,"alternative-id":["10.3389\/fpubh.2019.00151"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2019.00151","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,11]]},"article-number":"151"}}